Publicaciones en las que colabora con Pau Llácer Iborra (23)

2024

  1. Combining loop with thiazide diuretics in patients discharged home after a heart failure decompensation: Association with 30-day outcomes

    European Journal of Internal Medicine

  2. Improvement in left atrial strain following ferric carboxymaltose in heart failure: an analysis of the Myocardial-IRON trial

    ESC Heart Failure, Vol. 11, Núm. 2, pp. 1258-1262

  3. Noncardiovascular morbidity and mortality across left ventricular ejection fraction categories following hospitalization for heart failure

    Revista Espanola de Cardiologia, Vol. 77, Núm. 3, pp. 206-214

2023

  1. Chronotropic index and long-term outcomes in heart failure with preserved ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 511-518

2022

  1. Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction

    Scientific Reports, Vol. 12, Núm. 1

  2. Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure

    Revista Espanola de Cardiologia, Vol. 75, Núm. 4, pp. 316-324

  3. Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure

    European Journal of Internal Medicine, Vol. 95, pp. 67-73

  4. Sex-Related Differences in Mortality Following Admission for Acute Heart Failure Across the Left Ventricular Ejection Fraction Spectrum

    Journal of the American Heart Association, Vol. 11, Núm. 1

  5. Short-Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial-IRON Trial

    Journal of the American Heart Association, Vol. 11, Núm. 7, pp. e022214

2021

  1. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review

    European Journal of Heart Failure, Vol. 23, Núm. 9, pp. 1445-1457

  2. Clinical utility of antigen carbohydrate 125 for planning the optimal length of stay in acute heart failure

    European Journal of Internal Medicine, Vol. 92, pp. 94-99

  3. Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction

    Revista Espanola de Cardiologia, Vol. 74, Núm. 7, pp. 616-623

  4. Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction

    Journal of the American College of Cardiology, Vol. 78, Núm. 21, pp. 2042-2056

  5. Soluble ST2 and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction

    Journal of Cardiac Failure, Vol. 27, Núm. 4, pp. 427-434

2020

  1. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

    American Journal of Medicine, Vol. 133, Núm. 3, pp. 370-380.e4

  2. Early Spot Urinary Sodium and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction

    CardioRenal Medicine, Vol. 10, Núm. 5, pp. 362-372

  3. Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial

    Journal of the American Heart Association, Vol. 9, Núm. 4

  4. Short-term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial-IRON trial

    ESC Heart Failure, Vol. 7, Núm. 6, pp. 4222-4230

2018

  1. Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): Study design

    Clinical Cardiology, Vol. 41, Núm. 6, pp. 729-735

2017

  1. Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design

    Revista Espanola de Cardiologia, Vol. 70, Núm. 12, pp. 1067-1073